Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-28
2006-11-28
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S406000
Reexamination Certificate
active
07141599
ABSTRACT:
Treatment with a cyclooxygenase-2 inhibitor and a leukotriene B4receptor antagonist is described as being useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune diseases.
REFERENCES:
patent: 4595699 (1986-06-01), Terada et al.
patent: 4871771 (1989-10-01), Gleason et al.
patent: 4889935 (1989-12-01), Musser
patent: 4923891 (1990-05-01), Deason et al.
patent: 4970234 (1990-11-01), Djuric et al.
patent: 5210208 (1993-05-01), Huang et al.
patent: 5212198 (1993-05-01), Djuric et al.
patent: 5232948 (1993-08-01), Huang et al.
patent: 5246965 (1993-09-01), Main
patent: 5256686 (1993-10-01), Konno et al.
patent: 5272178 (1993-12-01), Mueller et al.
patent: 5310951 (1994-05-01), Djuric et al.
patent: 5344991 (1994-09-01), Reitz et al.
patent: 5366982 (1994-11-01), Dereu et al.
patent: 5380738 (1995-01-01), Norman et al.
patent: 5380740 (1995-01-01), Djuric et al.
patent: 5384318 (1995-01-01), Eggler et al.
patent: 5393790 (1995-02-01), Reitz et al.
patent: 5434178 (1995-07-01), Talley et al.
patent: 5446035 (1995-08-01), Neef et al.
patent: 5466863 (1995-11-01), Heidt et al.
patent: 5474995 (1995-12-01), Ducharme et al.
patent: 5521207 (1996-05-01), Graneto
patent: 5633272 (1997-05-01), Talley et al.
patent: 5700816 (1997-12-01), Isakson et al.
patent: 5916905 (1999-06-01), Weier et al.
patent: 6096728 (2000-08-01), Collins et al.
patent: 6172096 (2001-01-01), Gregory et al.
patent: 6617345 (2003-09-01), Gregory et al.
patent: 4228201 (1994-03-01), None
patent: 485 111 (1992-05-01), None
patent: WO 94/02448 (1994-02-01), None
patent: WO 94/04522 (1994-03-01), None
patent: WO 94/13635 (1994-06-01), None
patent: WO 94/15932 (1994-07-01), None
patent: WO 94/20480 (1994-09-01), None
patent: WO 94/26731 (1994-11-01), None
patent: WO 94/27980 (1994-12-01), None
patent: WO 95/00501 (1995-01-01), None
patent: WO 95/15316 (1995-06-01), None
patent: WO 96/03385 (1996-02-01), None
patent: WO 96/03387 (1996-02-01), None
patent: WO 96/03388 (1996-02-01), None
patent: WO 96/06840 (1996-03-01), None
patent: WO 96/41645 (1996-12-01), None
Pollock et al., Drug Metabolism and Disposition, abstract, 1989, 17(6), 595-9.
Badger et al., IMMUNOPHARM, 4, 149 (1982).
Bartlett et al., Drugs Exptl. Clin. Res., 15, 521 (1989).
Basmajian et al., “Acute Back Pain and Spasm, A Controlled Multicenter Trial of Combined Analgesic and Antispasm Agents.” Acute Back Pain, 1988.
Beaver, Am. J. Med. 77, 38 (1984).
Belcher et al., “Circulating Concentrations of Histamine, Neutrophil Chemotactic Activity, and Catecholamines During the Refractory Period in Exercise-Induced Asthma.” The Journal of Allergy and Clinical Immunology, 1988, pp. 100-110, vol. 81, No. 1.
Braun et al., Proc. Am. Soc. Clin. Oncol., 4, 21 Meeting, 223 (1985).
Breedveld, Scan. J. Rheumatol, 23 (Supp. 100), 31 (1994).
Caplus abstract 1996:225716, Nickerson-Nutter et al., The effects of Leukotriene . . . Mar. 1996.
Caplus 1996:582169, Zhang Wenyu et al., Tumor Necrosis, Jun. 1996.
Chang et al., “Prevention of ocular Inflammation by Matrine, Prednisolone, and Cyclooxygenase and Lipoxygenase Inhibitors.” Acta Pharmacologica Sinica, 1991, pp. 121-125, vol. 12, No. 2.
Fimiani et al., EOS-Revista di Immunologia and Immunofarmacologia, 13, 58 (1993).
Fossaluzza et al., “Combined Therapy with Cyclobenzaprine and Ibuprofen in Primary Fibromyalgia Syndrome.” Int. J. Clin. Pharm. Res., 1992, pp. 99-102, vol. XII, No. 2.
Fung-Leung et al., Transplantation, 60, 362 (1995).
Greenwald, et al., “Tetracyclines Suppress Matrix Metalloproteinase Activity in Adjuvant Arthritis and in Combination with Flurbiprofen, Ameliorate Bone Damage.” The Journal of Rheumatology, 1992, pp. 927-938, vol. 19, No. 6.
Guth et al., Pro. Natl. Acad. Sci. USA, 91, 12308 (1994).
Hughes et al., Dermatology, 184, 54 (1992).
Latter et al., J. Surg. Res., 43, 246 (1987).
Lightman and P. Watson, Am. J. Opthalmol., 108, 95 (1989).
Pollock et al., “Pharmacokinetics analysi9s of cyclosporine in adjuvant arthritic rats”, Drug Metabolism and Disposition, 17(6), 595-9, abstract, 1989.
Seideman et al., Acta Orthop. Scand., 64, 285 (1993).
Seifert and Engler, Curr. Med. Res. Opin., 7, 38 (1980).
Shaw and Greatorex, Adv. Prostaglandin, Thromboxane, Leukotriene Res., 13, 219 (1985).
Shelby et al., Transplantation Proc, 19, 1435 (1987).
Stewart et al., Clin. Pharmacol. Ther., 47, 540 (1990).
Tarayre et al., Arzneim.-Forsch./Drug Res., 40, 1125 (1990).
Tramposch, Inflammation, 17, 531 (1993).
Teicher et al., Cancer Chemother. Pharmacol, 33, 515 (1994).
Willkens and Segre, Arthritis Rheum, 19, 677 (1976).
Anderson Gary
Gregory Susan A
Isakson Peter G.
Kwon Brian S.
Low Christopher S. F.
Pharmacia Corporation
Pharmacia Corporation
LandOfFree
Immunosuppressive effects of administration of a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunosuppressive effects of administration of a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunosuppressive effects of administration of a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3693716